// App-Quantinova.ai

2687 : A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Researchers

Presenter

  • Fangxin Hong

Principal Investigators

  • Ivana N. Micallef

  • Randy D. Gascoyne

  • Ahmet Dogan

  • Henry Wagner Jr

  • Ranjana H. Advani

  • Brad S. Kahl

  • Sandra J. Horning

Medical Centers

  • Department of Medical Oncology, BC Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • Presenilin 2

  • Creatinine

  • Lactate dehydrogenase

Drug/Treatment

  • Ibritumomab tiuxetan with yttrium-90

  • Rituximab

  • Ibritumomab tiuxetan; Zevalin

Outcome

  • N/A

Study Design

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved